IQWiG<p>European <a href="https://wisskomm.social/tags/HTA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HTA</span></a> agencies and the <a href="https://wisskomm.social/tags/EMA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EMA</span></a> developed joint positions for better <a href="https://wisskomm.social/tags/evidence" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>evidence</span></a></p><p>A key result of the workshops: Drug studies should be designed in such a way that they address both regulatory questions and the essential research questions of benefit assessments.</p><p>Our press release: <a href="https://www.iqwig.de/en/presse/press-releases/press-releases-detailpage_143936.html" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">iqwig.de/en/presse/press-relea</span><span class="invisible">ses/press-releases-detailpage_143936.html</span></a></p>